Clinical Trial Update: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING